MobiHealth News September 13, 2021
The new initiative will begin with a focus on gastric cancer.
With an eye on the oncology space, Israeli startup Medial EarlySign has inked a deal with pharma giant Roche Diagnostics International to commercialize an artificial intelligence tool that helps detect cancer early. As part of the collaboration agreement, the pair will develop, clinically validate and then commercialize the product.
Initially the companies will focus on the gastric cancer space. The clinical decision support tool will use EarlySign’s software that incorporates lab results, EHR data and other clinical care.
WHY IT MATTERS
According to the American Cancer Society, stomach cancer accounts for roughly 1.5% of all new cancers diagnosed in the U.S. In fact, in 2021 the...
Today's Sponsors
Today's Sponsor